|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6700 - 0.6700|
|52 Week Range||0.6500 - 0.9500|
|Beta (5Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
RedHill's (RDHL) CTA gets approval in the United Kingdom to start a phase II/III study on opaganib for patients hospitalized with severe COVID-19 infection and pneumonia.
RedHill (RDHL) submits a Clinical Trial Application in Russia for a phase II/III study on opaganib to treat patients detected with severe COVID-19 infection and pneumonia. Stock up.
At this time, I would like to introduce to the conference call RedHill's CEO, Mr. Dror Ben-Asher; Mr. Micha Ben Chorin, RedHill's Chief Financial Officer; Mr. Rick Scruggs, RedHill's Chief Commercial Officer; and Mr. Gilead Raday, RedHill's Chief Operating Officer. Before we begin, we will read from RedHill's safe harbor statement.
Shares of Redhill Biopharma (NASDAQ:RDHL) rose 4.6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 66.67% year over year to ($0.05), which beat the estimate of ($0.24).Revenue of $1,056,000 decreased by 39.21% from the same period last year, which missed the estimate of $4,380,000.Looking Ahead Redhill Biopharma hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 27, 2020View more earnings on RDHLTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/cgzdt8vgTechnicals Company's 52-week high was at $9.1252-week low: $3.26Price action over last quarter: Up 51.80%Company Profile Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.See more from Benzinga * 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session * 17 Healthcare Stocks Moving In Friday's Pre-Market Session * Stocks That Hit 52-Week Highs On Tuesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.Suddenly, hundreds of such companies are redirecting resources in an effort to find a vaccine or treatment that could potentially halt the virus' spread. This has made the biotech space one of the few hot spots in a historically bad month for stocks.The shelter-in-place orders in the U.S. and other countries have also made it difficult for many of these companies to communicate directly with investors. This is especially challenging for biotech companies, which are often more communicative with investors than companies in other industries. Expensive drug trial and capital raising cycles, make constant communication with investors essential, according to John Viglotti, senior vice president of corporate services and investor access at OTC Markets."They are faced with a constant need to raise capital to fund clinical trials, and these clinical trials are not stopping," he said. "The life science business is certainly continuing."In an effort to bridge that gap between investors hungry for information and companies trying to reach them, OTC Markets is hosting the first Virtual Life Science Investor Forum on March 26. The online-only conference will consist of investor presentations from seven companies in five countries. Some will be giving updates on their COVID-19 treatments."Certainly with what's going on with the coronavirus pandemic, it just makes it that much more relevant," said Jason Paltrowitz, executive vice president of corporate services at OTC Markets. "The public at large is certainly interested in COVID-19, but from an investor perspective there are great opportunities."According to Viglotti, over 200 life sciences companies have previously participated in virtual investor conferences, making it one of the most popular sectors to participate in the conference series."It was really done with the realization that there are so many pre-revenue, early stage private life science companies that are just starved for attention," Paltrowitz said of this week's conference. "And we thought being able to host a series of virtual conferences would help."Below is the schedule for the conference. Each presentation is followed by a virtual Q&A session with attendees and is available on demand.To learn more about attending Thursday's conference, click here.9:30 AM ET RedHill Biopharma Ltd. (NASDAQ: RDHL) Speaker: Guy Goldberg, Chief Business Officer About: RedHill is a specialty biopharmaceutical company focused on gastrointestinal diseases. RedHill has commercial operations in the U.S., with a sales force promoting several gastrointestinal drugs across the U.S., including RedHill's recently FDA approved drug, Talicia®. RedHill also has a robust development pipeline with several late-stage development programs which have successfully completed Phase 3 studies.10:00 AM ET Nuvo Pharmaceuticals Inc. (OTCQX: NRIFF) Speakers: Jesse Ledger, President & Chief Executive Officer, and Kelly Demerino, Interim Chief Financial Officer About: Nuvo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.10:30 AM ET Orexo AB (OTCQX: ORXOY) Speaker: Nikolaj Sørensen, President & CEO About: Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv® for treatment of opioid use disorder.11:00 AM ET Emmaus Life Sciences, Inc. (OTCQB: EMMA) Speakers: Dr. Yutaka Niihara, Chairman and Chief Executive Officer, and Jay Sherwood Chief Financial OfficerAbout: Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Its FDA-approved Endari® (prescription grade L-glutamine oral powder) is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.11:30 AM ET Moleculin Biotech, Inc. (NASDAQ: MBRX) Speaker: Walter Klemp, Founder, President, CEO & Chairman About: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.12:00 PM ET Lexaria Bioscience Corp. (OTCQX: LXRP) Speaker: Chris Bunka, CEO About: Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way API's enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.12:30 PM ET Beroni Group Ltd. (OTCQX: BNIGF) Speakers: Jacky Zhang, Chairman and CEO, and Peter Wong, Group CFO About: Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) with business presence in Australia, China, Japan and the USA. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases.To learn more about attending Thursday's conference, click here.Photo by ThisisEngineering RAEng on UnsplashSee more from Benzinga * There's A New Tool That Helps Investors Understand The Corporate Structure Of US Banks * 10 International ADR Companies That Are Conducting Virtual Investor Presentations This Week * Despite Volatility, FANG Continues to Prove Its Popularity(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
RedHill Biopharma Ltd's said on Monday its three-drug combination therapy to treat Helicobacter pylori bacterial infections had been approved by the U.S. Food and Drug Administration, sending its shares up 25%. The drug, Talicia, is an oral capsule comprising two antibiotics, amoxicillin and rifabutin, as well as omeprazole, a common treatment for heartburn. The Israel-based company said the drug was designed to address the high resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies.
The U.S. Food and Drug Administration has approved RedHill Biopharma Ltd's drug to treat infections caused by bacteria known as Helicobacter pylori, the Israel-based company said on Monday. RedHill expects to launch the drug, Talicia, in the United States in the first quarter next year. Helicobacter pylori infection affects over 50% of the population worldwide, according to Redhill, and is one of the strongest risk factor for the development of gastric cancer.
The FDA worked overtime in October , deciding on the fate of several therapies and treatment options. Most reviews produced positive outcomes. Three new molecular entities, or NMEs, were approved in October, ...
Earnings, clinical trial readouts and positive FDA verdicts catalyzed fairly robust performances by biotech stocks last week. Biogen Inc (NASDAQ: BIIB )'s about-face with respect to its Alzheimer's drug ...
No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .